药物相互作用研究如何影响药品说明书:1998至2022年FDA批准新分子实体的调查
该研究分析了1998至2022年FDA批准的新分子实体药品说明书中药物相互作用(DDI)信息,重点探讨管理建议及依据来源。结果显示76.2%的新分子实体说明书包含至少1条DDI建议,共8992对独特DDI组合,其中48.5%提供了可操作的管理策略。最常见依据为基于处置途径的预测(43.5%)和临床药代动力学(PK)DDI研究(36.7%),且PK研究中药物暴露变化程度与可操作说明书建议呈正相关(P < 0.001)。
要点
- 76.2%的新分子实体说明书含至少1条DDI建议,共8992对DDI组合,48.5%有可操作管理策略。
- DDI建议最常见依据为处置途径预测(43.5%)和临床PK DDI研究(36.7%)。
- 75.2%的DDI建议机制涉及药物代谢酶或转运体,最常见为CYP3A诱导剂/抑制剂(38.8%)。
核心结论
- 多数FDA批准新分子实体说明书包含DDI建议,但仅约半数提供可操作管理策略。
- PK DDI研究中药物暴露变化程度与说明书建议的可操作性正相关(P < 0.001)。
研究设计与样本
- 研究提取1998至2022年FDA批准的新分子实体药品说明书和临床药理学审评文件中的数据元素。
主要发现
- 76.2%的新分子实体说明书包含至少1条DDI建议,共8992对独特DDI组合。
- 48.5%的DDI组合推荐了可操作的管理策略。
- DDI建议最常见依据为处置途径预测(43.5%)和临床PK DDI研究(36.7%)。
- 抗病毒药(39.2)、精神科药(24.2)和生殖领域药物(23.1)平均每批准品种建议数最多。
- 肿瘤药(71.9%)、肾内科药(71.4%)和医学影像药(63.6%)可操作建议百分比最高。
关键数值与推荐
- 75.2%的DDI建议机制涉及药物代谢酶或转运体。
- 最常见机制为CYP3A诱导剂/抑制剂(占相互作用38.8%)、CYP3A底物(24.4%)和CYP2C19诱导剂/抑制剂(15.8%)。
临床怎么用
- 临床药师可参考说明书DDI建议中的可操作管理策略,结合处置途径预测和PK研究证据进行用药决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug-drug interactions (DDIs) are a major cause of adverse drug events and drug inefficacy. To mitigate their clinical burden, it is essential for drug labeling to provide actionable DDI recommendations to clinicians. This investigation analyzed DDI information included in US Food and Drug Administration (FDA) labeling over the past two decades, focusing on DDI management recommendations and the information sources that served as their basis. Data elements were extracted from drug labels and clinical pharmacology reviews for new molecular entities (NMEs) approved by the FDA between 1998 and 2022. Drug labels for 76.2% of NMEs contained ≥1 DDI recommendation, yielding a total of 8,992 unique DDI pairs. Actionable management strategies were recommended for 48.5% of DDI pairs. The most common sources informing DDI recommendations were predictions based on disposition pathways (43.5%) and clinical pharmacokinetic (PK) DDI studies (36.7%). Antivirals (39.2), psychiatry (24.2), and reproduction (23.1) were the therapeutic areas with the most average recommendations per approval, while oncology (71.9%), nephrology (71.4%), and medical imaging (63.6%) were the therapeutic areas with the highest percentages of actionable recommendations. The underlying mechanisms for 75.2% of DDI recommendations involved drug-metabolizing enzymes or drug transporters, with the most common being CYP3A inducers/inhibitors (38.8% of interactions), CYP3A substrates (24.4%), and CYP2C19 inducers/inhibitors (15.8%). The extent of drug exposure changes in PK DDI studies was positively associated with actionable labeling recommendations (P < 0.001). In conclusion, our findings identify considerations to enhance the efficiency and completeness of studying DDIs and communicating DDI management recommendations in drug labeling.
引用
- Shugg T, Springer AN, Gafari Y, et al. How Drug-Drug Interaction Studies Inform Drug Labeling: A Survey of US Food and Drug Administration-Approved New Molecular Entities from 1998 to 2022. Clin Pharmacol Ther. 2026. PMID: 42257440. doi:10.1002/cpt.70264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。